ZONISAMIDE capsule United States - English - NLM (National Library of Medicine)

zonisamide capsule

physicians total care, inc. - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide 50 mg - zonisamide is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonisamide is contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. the abuse and dependence potential of zonisamide has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal studies, zonisamide did not demonstrate abuse liability and dependence potential. monkeys did not self-administer zonisamide in a standard reinforcing paradigm. rats exposed to zonisamide did not exhibit signs of physical dependence of the cns-depressant type. rats did not generalize the effects of diazepam to zonisamide in a standard discrimination paradigm after training, suggesting that zonisamide does not have abuse potential of the benzodiazepine-cns depressant type.

VITAMIN D- ergocalciferol capsule United States - English - NLM (National Library of Medicine)

vitamin d- ergocalciferol capsule

aphena pharma solutions - tennessee, llc - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

hydrochlorothiazide- Hydrochlorothiazide tablet United States - English - NLM (National Library of Medicine)

hydrochlorothiazide- hydrochlorothiazide tablet

caraco pharmaceutical laboratories, ltd. - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - tablet - 25 mg - hydrochlorothiazide tablet, usp is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. hydrochlorothiazide tablet, usp has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. hydrochlorothiazide tablet, usp is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. thiazides are indicated in pregnancy when ed

DESMOPRESSIN ACETATE solution United States - English - NLM (National Library of Medicine)

desmopressin acetate solution

sun pharmaceutical industries, inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate 0.1 mg in 1 ml - central cranial diabetes insipidus: desmopressin nasal spray solution, usp 0.01% is indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. it is ineffective for the treatment of nephrogenic diabetes insipidus.   the use of desmopressin nasal spray solution, usp 0.01% in patients with an established diagnosis will result in a reduction in urinary output with increase in urine osmolality and a decrease in plasma osmolality. this will allow the resumption of a more normal life-style with a decrease in urinary frequency and nocturia.   there are reports of an occasional change in response with time, usually greater than 6 months. some patients may show a decreased responsiveness, others a shortened duration of effect. there is no evidence this effect is due to the development of binding antibodies but may be due to a local inactivation of the p

CAFFEINE CITRATE injection
CAFFEINE CITRATE solution United States - English - NLM (National Library of Medicine)

caffeine citrate injection caffeine citrate solution

sun pharmaceutical industries, inc. - caffeine citrate (unii: u26eo4675q) (caffeine - unii:3g6a5w338e) - caffeine citrate 20 mg in 1 ml - caffeine citrate injection and caffeine citrate oral solution are indicated for the short term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age. caffeine citrate injection and caffeine citrate oral solution are contraindicated in patients who have demonstrated hypersensitivity to any of its components.

HYDROXYZINE HYDROCHLORIDE- hydroxyzine hydrochloride  tablet United States - English - NLM (National Library of Medicine)

hydroxyzine hydrochloride- hydroxyzine hydrochloride tablet

caraco pharmaceutical laboratories, ltd. - hydroxyzine hydrochloride (unii: 76755771u3) (hydroxyzine - unii:30s50ym8og) - for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. as a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates, so their use in preanesthetic adjunctive therapy should be modified on an individual basis. atropine and other belladonna alkaloids are not affected by the drug. hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. the effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. the physician should reassess periodically the usefulness of the drug for the individual patient. hydroxyzine, when administered t

HYDROCODONE BITARTRATE AND ACETAMINOPHEN tablet United States - English - NLM (National Library of Medicine)

hydrocodone bitartrate and acetaminophen tablet

rebel distributors corp - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - hydrocodone bitartrate and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain. hydrocodone bitartrate and acetaminophen tablets should not be administered to patients who have previously exhibited hypersensitivity to hydrocodone or acetaminophen. patients known to be hypersensitive to other opioids may exhibit cross-sensitivity to hydrocodone. hydrocodone bitartrate and acetaminophen tablets contain hydrocodone, an opioid agonist, and is a schedule iii controlled substance. hydrocodone bitartrate and acetaminophen, and other opioids, used in analgesia can be abused and are subject to criminal diversion.   addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. it is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. drug addiction is a treatable disease utilizing a

ZONISAMIDE capsule United States - English - NLM (National Library of Medicine)

zonisamide capsule

stat rx usa llc - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonisamide is contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. the abuse and dependence potential of zonisamide has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal studies, zonisamide did not demonstrate abuse liability and dependence potential. monkeys did not self-administer zonisamide in a standard reinforcing paradigm. rats exposed to zonisamide did not exhibit signs of physical dependence of the cns-depressant type. rats did not generalize the effects of diazepam to zonisamide in a standard discrimination paradigm after training, suggesting that zonisamide does not have abuse potential of the benzodiazepine-cns depressant type.

BENZONATATE capsule United States - English - NLM (National Library of Medicine)

benzonatate capsule

life line home care services, inc. - benzonatate (unii: 5p4dhs6enr) (benzonatate - unii:5p4dhs6enr) - benzonatate capsules are indicated for the symptomatic relief of cough. hypersensitivity to benzonatate or related compounds.

NIMODIPINE  - nimodipine  capsule United States - English - NLM (National Library of Medicine)

nimodipine - nimodipine capsule

caraco pharmaceutical laboratories, ltd. - nimodipine (unii: 57wa9qz5wh) (nimodipine - unii:57wa9qz5wh) - nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., hunt and hess grades i-v). the concomitant use of nimodipine with strong inhibitors of cyp3a4 such as some macrolide antibiotics (e.g., clarithromycin, telithromycin), some anti-hiv protease inhibitors (e.g., delaviridine, indinavir, nelfinavir, ritonavir, saquinavir), some azole antimycotics (e.g., ketoconazole, itraconazole, voriconazole) and some antidepressants (e.g., nefazadone) is contraindicated because of a risk of significant hypotension (see precautions, drug interactions ). there have been no reported instances of drug abuse or dependence with nimodipine.